Administering Insulin Glargine with Normal Fasting Glucose

Key Considerations

Insulin glargine is a long-acting basal insulin whose primary action is to restrain hepatic glucose production and limit hyperglycemia overnight and between meals, according to the American Diabetes Association 1, 2
A fasting blood glucose of 85 mg/dL is within normal range, indicating that the current basal insulin dose may be appropriate or potentially too high, as suggested by the American Diabetes Association 2
When administering insulin glargine with normal fasting glucose levels, monitor for signs of overbasalization, which include high bedtime-morning glucose differential, hypoglycemia, and high glucose variability, as recommended by the American Diabetes Association 2, 3

Assess for signs of overbasalization, including basal dose >0.5 units/kg/day, bedtime-morning glucose differential >50 mg/dL, and history of hypoglycemia, as indicated by the American Diabetes Association 1, 2, 3
Evaluate need for dose adjustment, considering fasting glucose consistently in target range (80-100 mg/dL) without hypoglycemic episodes, and adjust dose accordingly, as suggested by the American Diabetes Association 2, 4

For patients who are fasting, the basal insulin dose may need to be reduced by 25-35% if glucose levels are within goal range, as recommended by the American Diabetes Association 4
Patients with type 2 diabetes generally require higher daily doses (approximately 1 unit/kg) and have lower rates of hypoglycemia compared to those with type 1 diabetes, according to the American Diabetes Association 1
More cautious dosing may be needed in patients with hypoglycemia unawareness or autonomic neuropathy, as suggested by the American Diabetes Association 3

Regular self-monitoring of blood glucose, especially fasting levels and nocturnal readings, is recommended by the American Diabetes Association 2
Periodic reassessment of insulin dosing based on patterns in glucose readings is suggested by the American Diabetes Association 3
Education of patients on recognition and management of hypoglycemia is recommended by the American Diabetes Association 2